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 2 
Highlights 1 
 Regulation of SRPK1 (Serine Arginine-rich Protein Kinase 1)-SRSF1 (Serine 2 
Arginine-rich Splicing Factor 1) mediated alternative RNA splicing in the spinal 3 
cord modulates neuropathic pain. 4 
 SRSF1 is located in myelinated sensory afferent terminals. 5 
 Vascular Endothelial Growth Factor-A (VEGF-A) expression regulates chronic 6 
pain at the level of the spinal cord.  7 
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Abstract 1 
Neuropathic pain results from neuroplasticity in nociceptive neuronal networks. Here 2 
we demonstrate that control of alternative pre-mRNA splicing, through the splice factor 3 
serine-arginine splice factor 1 (SRSF1), is integral to the processing of nociceptive 4 
information in the spinal cord.  5 
Neuropathic pain develops following a partial saphenous nerve ligation injury, at which 6 
time SRSF1 is activated in damaged myelinated primary afferent neurons, with 7 
minimal found in small diameter (IB4 positive) dorsal root ganglia neurons. Serine 8 
arginine protein kinase 1 (SRPK1) is the principal route of SRSF1 activation. Spinal 9 
SRPK1 inhibition attenuated SRSF1 activity, abolished neuropathic pain behaviors 10 
and suppressed central sensitization. SRSF1 was principally expressed in large 11 
diameter myelinated (NF200-rich) dorsal root ganglia sensory neurons and their 12 
excitatory central terminals (vGLUT1+ve) within the dorsal horn of the lumbar spinal 13 
cord.  14 
Expression of pro-nociceptive VEGF-Axxxa within the spinal cord was increased after 15 
nerve injury, and this was prevented by SRPK1 inhibition. Additionally, expression of 16 
anti-nociceptive VEGF-Axxxb isoforms was elevated, and this was associated with 17 
reduced neuropathic pain behaviors. Inhibition of VEGF receptor-2 signaling in the 18 
spinal cord attenuated behavioral nociceptive responses to mechanical, heat and 19 
formalin stimuli, indicating that spinal VEGF receptor-2 activation has potent pro-20 
nociceptive actions. Furthermore, intrathecal VEGF-A165a resulted in mechanical and 21 
heat hyperalgesia, whereas the sister inhibitory isoform VEGF-A165b resulted in anti-22 
nociception. These results support a role for myelinated fiber pathways, and 23 
alternative pre-mRNA splicing of factors such as VEGF-A in the spinal processing of 24 
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neuropathic pain. They also indicate that targeting pre-mRNA splicing at the spinal 1 
level could lead to a novel target for analgesic development.  2 
 3 
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Abbreviations 1 
VEGF-A = Vascular Endothelial Growth Factor – A 2 
SRSF1 = Serine Arginine-rich Splicing Factor 1 3 
SRPK1 = Serine Arginine-rich Protein Kinase 1 4 
VEGFR2 = Vascular Endothelial Growth Factor Receptor 2 5 
PSNI = Partial Saphenous Nerve Ligation Injury  6 
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Introduction  1 
Insults to the peripheral nervous system usually result in pain and hypersensitivity to 2 
noxious (hyperalgesia) and innocuous (allodynia) stimuli. These abnormal sensations 3 
arise due to neuronal plasticity leading to alterations in sensory neuronal excitability. 4 
These alterations include peripheral sensitization [20], with enhanced evoked and on-5 
going activity in primary afferents, and central sensitization, responsible for the 6 
generation and maintenance of chronic pain. The most widely accepted model for 7 
establishment of central sensitization is that ectopic firing/increased activity in C-8 
nociceptive afferents drives altered spinal sensory processing, particularly the 9 
processing of A-fiber inputs, resulting in secondary hyperalgesia and allodynia (pain 10 
remote from an area of damage) [46,89,90] [42,74,97]. C-nociceptor changes are 11 
reported in the majority of studies of animal or human neuropathies [1,14,20,38,40,68-12 
70,96] (although not all e.g. [14,38]). Central sensitization can also occur through 13 
neuro-immune interactions, following injury-induced local immune cell infiltration and 14 
cytokine production/release [80]. After nerve injury there is activation of spinal glia, 15 
disruption of the blood-spinal cord barrier, and consequent infiltration of immune cells 16 
[16]. These events can alter the central processing of peripheral inputs, implicated in 17 
the development of chronic pain [27,39,76]. There is, however still debate on how the 18 
processing of A or C fiber inputs is differentially regulated to form the neuronal basis 19 
of chronic pain. 20 
During chronic pain, changes in the complement of proteins result in alterations in 21 
sensory neuron excitability, as recently demonstrated whereby expression of voltage 22 
gated potassium channels in the DRG is altered in ATF3 positive sensory neurons 23 
following nerve injury [79]. Furthermore, alternative mRNA splicing allows for 24 
functionally distinct proteins to arise from a single gene. This provides a vast repertoire 25 
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 7 
of actions from a limited source of transcripts, allowing for cell-specific and stimulus-1 
induced alteration in cellular function. Targeting regulation and expression of 2 
alternative RNA transcripts, and hence proteins, has been proposed as a potential 3 
route for novel drug discovery [73], but this has not been widely investigated with 4 
respect to nociception/analgesia.  5 
We recently demonstrated the analgesic effect of targeting alternative mRNA splicing, 6 
by inhibition of peripheral serine-arginine rich protein kinase 1, SRPK1 [35]. SRPK1 7 
controls phosphorylation of serine-arginine rich splice factor 1 (SRSF1), which is 8 
fundamental to the control of the vascular endothelial growth factor A (VEGF-A) family 9 
alternative splicing [2,8,59,60]. Inactive SRSF1 is located in the cytoplasm, but when 10 
phosphorylated by SRPK1 it translocates to the nucleus. There are two VEGF-A 11 
isoform families, VEGF-Axxxa and VEGF-Axxxb [31]  where xxx refers to the number of 12 
amino acids encoded, and a and b denote the terminal amino acid sequence. SRSF1 13 
phosphorylation results in preferential production of the proximal splice site isoforms, 14 
VEGF-Axxxa [59]. Little is understood about the contribution of VEGF-A proteins to 15 
nociceptive processing. VEGF receptor-2 (VEGFR2), the principal receptor activated 16 
by both isoform families, has been implicated in nociceptive processing in animal 17 
[29,35,50], and clinical studies [43]. VEGF-A isoforms and VEGFR2 are present in the 18 
spinal cord [6], and contribute to neuroregeneration and neuroprotection [83].  19 
We therefore tested the hypothesis that the SRPK1/SRSF1 system contributes to 20 
spinal nociceptive processing in rodent models of neuropathic pain, concentrating on 21 
the effects of SRPK1 inhibition, and VEGF-Axxxa/VEGFR2 signaling in central 22 
terminals of myelinated afferents.   23 
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Materials and Methods 1 
Animals 2 
Adult male Wistar rats (total 72; 250-350g, Harlan UK) and adult male 129Ola mice 3 
(total 20; 25-30g inbred strain) were used. Animals were provided food and water ad 4 
libitum. All animal procedures were carried out in laboratories at the University of 5 
Bristol in accordance with the U.K. Animals (Scientific Procedures) Act 1986 plus 6 
associated U.K. Home Office guidance, EU Directive 2010/63/EU, with the approval 7 
of the University of Bristol Ethical Review Group.  8 
 9 
Nociceptive Behavior 10 
Nociceptive behavioral testing was carried out as previously described [35]. All 11 
animals were habituated to both handling by the tester and the testing environment on 12 
the day prior to testing. Two days of baseline testing were carried out prior to any 13 
intervention (either drug or surgical) followed by testing post-intervention at discrete 14 
time-points as detailed in each experiment. Stimuli were applied to the partially 15 
innervated medial aspect of the plantar surface of the hindpaw, an area innervated by 16 
the saphenous nerve. Mechanical withdrawal thresholds were calculated from von 17 
Frey hair force response curves. Animals were housed in Perspex holding chambers 18 
with metal mesh floors (Ugo Basile) and allowed to habituate for 10 minutes. A range 19 
of calibrated von Frey hairs were applied to the plantar surface of the hindpaw (for a 20 
maximum of five seconds or until paw withdrawal), with a total of five applications per 21 
weighted hair. From these data, force response curves were generated and withdrawal 22 
values were calculated as the weight at which withdrawal frequency = 50%. Tactile 23 
allodynia was assessed in the metal mesh floored enclosures using a brush moved 24 
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across the plantar surface of the hindpaw where a withdrawal scored one, with no 1 
response zero. This was repeated a total of five times giving a maximum score of five 2 
per session. Cold allodynia: a single drop of acetone was applied to the plantar surface 3 
of the hindpaw using a 1ml syringe a maximum of five times giving a maximum score 4 
of five if the animal exhibited licking/shaking behavior in response to each application. 5 
Thermal hyperalgesia (Hargreaves test[30]): animals were held in Perspex enclosures 6 
with a glass floor. A radiant heat source was positioned under the hindpaw, and the 7 
latency was recorded for the time taken for the animal to move the hindpaw away from 8 
the stimulus. This was repeated three times and a mean value calculated for each test.  9 
Formalin Testing: animals were habituated to glass floored testing enclosures as 10 
above. A single 50µl injection of 5% formalin was administered to the plantar surface 11 
of the right hindpaw by intradermal injection. Immediately following formalin injection, 12 
animals were placed into the testing enclosures. Time (seconds) spent exhibiting pain-13 
like behaviors and the total number of pain-like behaviors was recorded in five minute 14 
bins for sixty minutes. Data are shown as the classical biphasic response with 15 
behavioral responses pooled for the first phase 0-15 minutes and second phase 20-16 
60 minutes. Blinding of nociceptive behavoural studies are routine in the laboratory 17 
however where animal welfare/experimental design prohibits this, it cannot be 18 
implemented. For instance, in nerve-injured animals blinding is not possible as 19 
controls are naïve. The lack of blinding may have introduced some subjective bias into 20 
these experiments, which is in part mitigated by behavioural data is supported by the 21 
inclusion of experiments in which measurements are not subjective (e.g. in vivo 22 
noxious e.m.g. recording, expression analysis, and neuronal activation using c-fos).   23 
Electromyographic Experiments 24 
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A well-defined method for minimally invasive preferential selection of either C- or A- 1 
fibre mediated nociceptive pathways was used [93,94]. Noxious withdrawal responses 2 
to A- and C-nociceptor selective stimulation were carried out as previously described 3 
[44,45,53], by measurement of electromyographic activity in biceps femoris. Animals 4 
were anaesthetized using isoflurane induction (4% in oxygen), and the external jugular 5 
vein and trachea were cannulated to allow maintenance of airway and anesthesia. 6 
Following surgery, anesthesia was switched to alfaxalone (~30mg/kg/hr i.v.), and 7 
animals were maintained at a steady level of anesthesia by continuous pump perfusion 8 
via the jugular vein for the remainder of the experiment. Bipolar electrodes were made 9 
with Teflon coated stainless steel wire (Advent Research Materials, Oxford UK) 10 
implanted into the bicep femoris. EMG recordings were amplified and filtered by a 11 
combination of in-house built and Neurolog preamplifier and band pass filters 12 
(Digitimer Neurolog System). Animals were maintained at a depth of anesthesia where 13 
a weak withdrawal to noxious pinch could be elicited for the duration of the experiment. 14 
A- and C-cutaneous nociceptors were preferentially activated to elicit withdrawal reflex 15 
EMGs using a well-characterized contact heating protocol [44,45,53]. Two different 16 
rates of heating (2.5OC/s and 7.5OC/s) were applied to the dorsal surface of the left 17 
hindpaw as these are known to preferentially activate slow/C-nociceptors (2.5oCs-1) 18 
and fast/A nociceptors (7.5oCs-1) respectively. Contact skin temperature at the time 19 
of onset of the EMG response was taken as the threshold. A cutoff of 58oC for A-20 
nociceptors, 55oC for C-nociceptors was put in place to prevent sensitization if no 21 
response was elicited. If a withdrawal response was not elicited, threshold was taken 22 
as cut-off +2oC [22]. Three baseline recordings were performed before i.t. drug 23 
injection with a minimum 8 minutes inter-stimulus interval, and alternating heating 24 
rates, to prevent sensitization or damage to the paw. Digitized data acquisition, digital 25 
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to analogue conversion, and offline analyses were performed using a CED Micro1401 1 
Mark III and Spike2 version 7 software (Cambridge Electronic Design, UK).   2 
Nerve injury model 3 
The partial saphenous nerve ligation injury (PSNI) model was used to induce 4 
mechanical and cold allodynia, as described previously [34,84]. Under isoflurane 5 
anesthesia (3% in O2,), the saphenous nerve was exposed via an incision made along 6 
the inguinal fossa region of the right hind leg. Approximately 50% of the nerve was 7 
isolated and tightly ligated using 4.0 silk suture, and the incision was closed using size 8 
4.0 sterile silk suture. 9 
Drugs and drug delivery 10 
I.t. injections were carried out under isoflurane (4% in oxygen) anesthesia, using 0.5ml 11 
insulin syringes (29 gauge, Terumo) in rats and mice. For i.t. administration, 10 µl 12 
injections were made in the midline of the vertebral column through the intervertebral 13 
space between lumbar vertebrae five and six. The injection was deemed to be in the 14 
correct place when it evoked a tail flick response. Rats were used for i.t. anti-VEGF-15 
Axxxb experiments, as the 56/1 mouse monoclonal antibody had not been validated in 16 
mice at that time.  All nociceptive behavioural testing was carried out one hour after 17 
intrathecal injection as initial experiments indicated that responses to i.t. PTK peaked 18 
at 1 hour, and returned to normal by 2 hours after injection. 19 
All drugs were made up as stock concentrations and then diluted to working 20 
concentration in phosphate buffered saline (PBS) as described in each experiment. 21 
Vehicle controls were used for each drug.  PTK787 (LC laboratories, USA) was 22 
dissolved in polyethylene glycol (PEG) 300/PBS, with the final PEG 300 concentration 23 
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at 0.002%. ZM323881 (Tocris, UK) was made up in DMSO/PBS and given 1 
intrathecally at a final concentration of 100nM ZM323881/0.001% DMSO. Mouse 2 
monoclonal VEGF-A165b antibody 56/1 (AbCam ab14994; MRVL56/1), recombinant 3 
human (rh)VEGF-A165A (R&D systems, UK) and rhVEGF-A165b (R&D Systems UK) 4 
were all dissolved in PBS. SRPIN340 (N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl] 5 
iso nicotinamide; SRPK inhibitor [25]  purchased from Ascent Scientific, Bristol, UK) 6 
was dissolved in DMSO and diluted to final concentrations in PBS (to a final DMSO 7 
concentration of 0.03%). All peptides and concentrations used have been previously 8 
shown to exert functional effects in neurons and/or other biological systems [9,35,63]. 9 
SRPIN340 has been used in several other studies, different pathological states, and 10 
was used at a known functional concentration (10μM), as previously described 11 
[2,35,51].  12 
Immunohistochemistry 13 
Rats were terminally anesthetized with sodium pentobarbital overdose (i.p. 60mg/kg) 14 
and were perfused transcardially with saline followed by 4% paraformaldehyde. The 15 
L3-4 segments of the lumbar enlargement, containing the central terminals of 16 
saphenous nerve neurons [64], and L3-L4 dorsal root ganglia were removed, post 17 
fixed in 4% paraformaldehyde for 2 hours and cryoprotected in 30% sucrose for 12 h. 18 
Tissue was stored in OCT embedding medium at -80oC until processing. A cryostat 19 
was used to cut spinal cord (20µm) and dorsal root ganglia (8µm) sections that were 20 
thaw mounted onto electrostatic glass slides. Slides were washed in phosphate 21 
buffered saline (PBS) solution 3 times for 5 minutes per incubation, and incubated in 22 
PBS 0.2% Triton X-100 for 5 minutes. Sections were blocked (5% bovine serum 23 
albumin, 10% fetal bovine serum, 0.2% Triton X-100 in PBS) for 2 hours at room 24 
temperature, and then incubated in primary antibodies diluted in blocking solution 25 
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overnight at 4oC. Sections were washed three times in PBS washes and incubated for 1 
2 h in secondary antibody (e.g. biotinylated or alexafluor-conjugated; 0.2% Triton X-2 
100 in PBS). For the third stage (i.e. streptavidin-alexfluor conjugate), incubations and 3 
washes were as described for the secondary antibody. Slides were washed in PBS 3 4 
times prior to coverslipping in Vectorshield (H1000 or H1200 containing DAPI for 5 
nuclear staining, Vector Laboratories). Images were acquired on either Nikon Eclipse 6 
E400 and a DN100 camera or Leica TCS SPE confocal microscope using Leica 7 
application suite (Tumor and Vascular Biology Laboratories’ imaging suite UoN). 8 
Primary antibodies used were as previously reported [2,59]: anti-ATF3 (rabbit 9 
polyclonal; 2μg/ml: Santa Cruz), anti-c-fos (rabbit polyclonal; 2μg/ml: Santa Cruz), 10 
anti-SRSF1 (goal polyclonal; 2μg/ml; sc-10255 Santa Cruz), anti-vGLUT1 (rabbit 11 
polyclonal, 60pg/ml, Synaptic Systems), anti-NF200 (mouse monoclonal; 1.4μg/ml; 12 
N0142 Sigma-Aldrich), anti-NeuN (mouse monoclonal, 1 in 100, Millipore). Use of anti-13 
VEGF-A and SRSF1 antibodies for both immunolocalisation and immunoblotting has 14 
been previously reported [2,8]. Secondary antibodies (1 in 1000 dilution and from 15 
Invitrogen unless stated): Alexafluor 488 goat anti-mouse, Alexafluor 488 chicken anti-16 
goat, Alexafluor 555 donkey anti-goat, Alexafluor 555 donkey anti-rabbit; biotinylated 17 
anti-rabbit (Stratech Scientific), Extravidin CY3 (Sigma-Aldrich). Dorsal root ganglia 18 
neuronal cell counts were performed using ImageJ analysis to measure neuronal area 19 
(μm2) [67]. The saphenous nerve is approximately equally derived from lumbar DRGs 20 
3 and 4 in rat and human [5,64,95]; the mean number of neurons per section was 21 
quantified from 10 non-sequential random L4 DRG sections per animal. Data are 22 
presented as the mean number of neurons per section and the experimental unit is 23 
the animal. The number of activated SRSF1-positive neurons (defined as those 24 
showing nuclear localization of SRSF1) was calculated as a percentage of total 25 
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neurons as designated by size (small<600μm2, medium 600μm2-1200μm2, 1 
large>1200μm2) [79]. The total number of DRG neurons quantified was ~5000 (100 2 
neurons per section, 10 per animal, 3 per group). Determination of SRSF1 spinal cord 3 
expression/localization was determined from 5 non-sequential random spinal cord 4 
sections per animal using Image J analysis. Images were converted to an 8-5 
bit/grayscale image then thresholding was applied across all acquired images to 6 
determine the area of positive staining. Areas of positive staining were then quantified 7 
across all sections and groups. Colocalisation was determined via coloc2 plugin in 8 
ImageJ. Controls for VEGF-A and SRSF1 immunofluorescence consisted of 9 
incubation with only secondary antibody (‘no primary’ control) or substitution of the 10 
primary antibody with a species matched IgG.  11 
Western blotting 12 
Naïve and PSNI rats (treated with i.t. vehicle or SRPIN340) were terminally 13 
anesthetized (i.p. 60mg/kg sodium pentobarbital) and perfused with saline solution. 14 
The lumbar region of the spinal cord was extracted and frozen immediately on dry ice, 15 
then stored at -80oC. Protein lysates (80μg/well) were prepared using lysis buffer 16 
(RIPA buffer, Sigma-Aldrich) with protease inhibitors (Sigma-Aldrich) and samples 17 
were homogenized. Protein extracts were stored at -80oC until required. Samples were 18 
run on a 4% stacking gel/12 % running SDS-PAGE gel (90V, 1hr 30min) and 19 
transferred (wet transfer) to nitrocellulose membrane for 1hr @ 100V. Membranes 20 
were then incubated with either α-SRPK1 (mouse; 1μg/ml; Sigma-Aldrich), α-SRSF1 21 
(ASF/SF2; rabbit; 0.5μg/ml; Abcam), α-SRSF1 (ASF/SF2; mouse; 0.5μg/ml; 22 
SantaCruz), α-Actin (SantaCruz; 2μg/ml) α-VEGF-A165b (mouse; 4μg/ml; Abcam;), α-23 
pan-VEGF-A (rabbit; Santa Cruz A20; 2μg/ml) or α-tubulin (mouse; 1 in 4000; Sigma-24 
Aldrich) antibodies and visualized with Femto chemoilluminescence kit (exposure 25 
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between 1 second and 1 minute,Thermo Scientific) or Licor IRdye secondary 1 
antibodies (as previously reported [2,25,59]) 2 
Statistical Analysis 3 
All data are represented as means ± SEM. Data were extracted and analyzed using 4 
Microsoft Excel 2010, Graphpad Prism v6 and ImageJ [67]. Nociceptive behavioral 5 
analyses were between-subjects designs comparing effects of drugs by two way 6 
ANOVA with post-hoc Bonferroni tests. In those experiments involving intrathecal and 7 
intraperitoneal administration of drugs in naïve animals, both hind paws were included 8 
in the analysis as replicates. EMG experiments used a within-subjects design and 9 
immunofluorescence experiments a between-subjects design with the effects of drug 10 
treatment compared to baseline values using one-way ANOVA with post-hoc 11 
Bonferroni tests. Immunofluorescence analysis of spinal cord (c-fos quantification) 12 
was taken from entirety of dorsal horn. DRG (SRSF1+ve) and spinal cord (c-fos) 13 
neuron counts were ascertained from multiple representative images, at least 10 per 14 
animal and the mean value of those 10 calculated. Coloc2 analysis (Image J plugin) 15 
was used to ascertain the pixel intensity spatial correlation (co-localization) of SRSF1 16 
and vGLUT1 staining in the spinal cord. This provides an automated measure of the 17 
correlation of pixel intensity for the two independent immunofluorescence channels for 18 
each sample, given as the Pearson’s correlation co-efficient [17,47]. Western blot 19 
analyses of SRSF1 and VEGF-A family expression were determined from ImageJ 20 
densitometry analysis (gel analysis plug in) and compared using Mann Whitney U 21 
tests. All F test statistics are described as a column factor with reference to 22 
drug/experimental grouping. NS designates not significant.  23 
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Results 1 
SRSF1 is predominantly expressed in myelinated neurons in rats 2 
SRPK1 and SRSF1 are key factors in the control of VEGF-Axxxa preferential splicing 3 
particularly in disease [2,59]. SRSF1 is expressed in the cytoplasm of dorsal root 4 
ganglia (DRG) neurons in naïve animals [35](Fig. 1A-C). Upon activation 5 
(phosphorylation), SRSF1 is known to translocate from the cytoplasm to the nucleus 6 
[2,59], where it is involved in pre-mRNA processing. Following PSNI, SRSF1 7 
immunoreactivity in sensory DRG neurons was found to be nuclear (Fig. 1E-G) in 8 
some but not all neurons.  Matched IgG (Fig. 1D) and omission of primary antibody 9 
(Fig.1H) controls showed no signal. PSNI injury induces activating transcription factor 10 
3 (ATF3) expression in injured DRG sensory neurons [9].  There was an increase in 11 
ATF3-positive DRG neurons after PSNI (Fig. 1I-K), with 43% of DRG neurons 12 
expressing ATF3 post-PSNI compared to only 1% in naïve animals (Fig. 1K). After 13 
PSNI, all nuclear localized SRSF1-positive (Fig 1L) DRG neurons (Fig 1M) were also 14 
ATF3 positive (Fig 1N), indicating nuclear SRSF1 was exclusively found in damaged 15 
neurons (Fig. 1O). This represents that 45% of ATF3 -positive neurons were also 16 
SRSF1 positive, with the remaining 55% of ATF3 positive neurons negative for 17 
SRSF1. 18 
SRSF1 was expressed predominantly in the cytoplasm of 96% of larger (cross 19 
sectional area >1200µm2) neurofilament-200 (NF200) positive DRG neurons in naïve 20 
animals (Fig. 2A-C, L), and 71% of medium (area 601-1200 µm2) neurons, but was in 21 
only a small proportion (14%) of neurons of area <600 µm2 (small, <30µm diameter). 22 
NF200 is a marker for myelinated neurons indicating that SRSF1 expression is 23 
principally found in the somata of A-fiber DRG neuronal population, but it was also 24 
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found in peripheral sensory nerve fibers in PSNI animals (Fig. 2I-K). Following PSNI, 1 
activated (nuclear) SRSF1 co-localized with ATF3 and NF200 in DRG sensory 2 
neurons (Fig. 2D-F), The size distribution of activated (nuclear) SRSF1 in injured 3 
neurons was similar to that in naives, -  69% of large cells, 21.5% of medium cells but 4 
a small proportion (1.7%) of small neurons. In contrast, only a minority of the IB4-5 
binding, largely unmyelinated DRG neurons from nerve-injured animals were positive 6 
for SRSF1 (Fig. 2G-H). The size distribution profile of DRG sensory neurons indicated 7 
that SRSF1-positive neurons are medium/large in size (Fig. 2L).  8 
 9 
SRSF1 immunofluorescence was also identified in the lumbar region of the spinal cord 10 
of PSNI rats, where it was co-localized with the marker of myelinated primary afferent 11 
central terminals, the vesicular glutamate transporter 1 (vGLUT1, Fig. 3A-C) 12 
[11,58,92]. There was an increase in SRSF1 expression in the central sensory 13 
terminals 2 days after PSNI, as assessed by immunofluorescence (Fig. 3D-I) and 14 
quantified by Western blot (Fig. 3J-K; p=0.055). Co-localization analysis of vGLUT1 15 
and SRSF1 staining showed a stronger colocalization in the PSNI animals (indicative 16 
of increased SRSF1 expression) in PSNI (Fig. 3L). vGLUT1 is found in large diameter 17 
myelinated neurons, and is not found in either the peptidergic or IB4-binding C-18 
nociceptor populations [11,62]. Furthermore, SRSF1 (Fig. 3M) was co-localized with 19 
vGLUT1 (Fig. 3M-O) in DRG sensory neurons. There was no SRSF1 expression in 20 
the contralateral dorsal horn of either naïve or PSNI rats, although vGLUT1 expression 21 
was evident, indicating that the increased spinal SRSF1 expression was associated 22 
with injury to peripheral neurons and not a systemic response (Fig. 3P-S). 23 
 24 
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Attenuation of SRSF1 mediated alternative splicing prevents A-nociceptor 1 
mediated neuropathic pain in rats 2 
The increased SRSF1 immunoreactivity in vGLUT1-positive central terminals after 3 
PSNI (Fig. 3) was accompanied by an increase in total VEGF-A expression in spinal 4 
cord (Fig. 4A-F) assessed with the pan-VEGF-A antibody A20 [2]). VEGF-A was also 5 
co-localized with SRSF1 in some, but not all central terminals (Fig. 4G-I). VEGF-Axxxb 6 
remained unchanged in spinal cord after PSNI whereas total (pan)-VEGF-A 7 
significantly increased (Fig. 4J&K). This indicates an increase in the expression of 8 
VEGF-Axxxa isoforms, resulting in a decrease in VEGF-Axxxb as a proportion of total-9 
VEGF-A (Fig. 4L).  10 
These results suggest that SRSF1 phosphorylation and activation at the level of the 11 
spinal cord is induced by PSNI, and is accompanied by a change of the balance of 12 
VEGF isoforms toward VEGF-Axxxa. As VEGF-A165a has been shown to be pro-13 
nociceptive, and VEGF-A165b anti-nociceptive [35], it is therefore possible that 14 
changes in SRSF1 and VEGF-A expression at the level of the spinal cord are 15 
associated with the development of neuropathic pain behaviors. SRSF1 activity is 16 
activated through phosphorylation by serine-arginine-rich protein kinase SRPK1 [2]. 17 
To test the hypothesis that PSNI neuropathic pain is dependent upon SRSF1 18 
activation, we inhibited SRPK1 in the spinal cord of rats, with intrathecal (i.t) injection 19 
of the SRPK1 antagonist, SRPIN340 (N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl] 20 
isonicotinamide, Ascent Scientific, Bristol UK) [24] (10µM i.t. injection) at the time of 21 
nerve injury surgery (time point day 0). SRPIN340 has been used extensively to inhibit 22 
SRPK1 activity and a multitude of studies have demonstrated its involvement with 23 
controlling alternative splicing for VEGF-A isoforms [2,51,59], through suppression of 24 
SR protein phosphorylation and stabilization [24]. SRPIN340 inhibits both SRPK1 and 25 
Hulse et al. 2016 
 
 19 
SRPK2 at concentrations equal or less than 10μM [24], and this has been shown 1 
previously to inhibit VEGF-Axxxa production in vitro [59] and in vivo [2].  PSNI induced 2 
a reduction in mechanical withdrawal thresholds in the ipsilateral hindpaw as 3 
expected, and this was blocked by i.t. SRPIN340 (Fig. 5A; PSNI+vehicle n=9, 4 
PSNI+SRPIN n=6). Tactile and cooling allodynia which also developed in the 5 
ipsilateral hindpaw (Figs. 5B & C) were also inhibited by SRPIN340. Contralateral 6 
hindpaws from vehicle and SRPIN340 treated groups did not differ from each other, 7 
indicating no effect of central SRPK1 inhibition on noxious processing from uninjured 8 
tissue. The PSNI model does not in itself lead to the development of heat hyperalgesia 9 
[34], but Hargreaves latencies did increase as a result of SRPIN340 treatment 10 
compared to vehicle treated PSNI animals, both ipsilateral (Fig. 5D) and contralateral 11 
(Fig. 5E) to the nerve injury, indicating a possible contribution of SRPK1/SRSF1 in 12 
normal nociceptive processing. SRPIN340 treatment also resulted in a significant 13 
inhibition of the increase in SRSF1 immunoreactivity in the central terminals of the 14 
dorsal horn of the spinal cord induced by PSNI (Fig. 6A-H). Furthermore, the 15 
administration of SRPIN340 resulted in increased distal splice site, anti-nociceptive 16 
isoform VEGF-Axxxb with no overall change in total VEGF-A expression (Fig. 7A), 17 
indicating a switch from proximal to distal splice site transcripts following SRPIN 18 
treatment in peripheral nerve injury (Fig. 7B-C). Intrathecal SRPIN340 not only blocked 19 
the development of nociceptive behaviors and altered alternative splicing in the dorsal 20 
horn, it also blocked indicators of central sensitization. The number of c-fos positive 21 
neurons in the spinal cord, a marker of central sensitization [36] as assessed by 22 
immunofluorescent staining (Fig. 7D), was increased after PSNI and was significantly 23 
reduced by i.t. SRPIN340 (Fig. 7E-F). SRPK1 protein expression within the spinal cord 24 
was not significantly altered following nerve injury alone (Fig. 6G) 25 
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 1 
VEGF-R2 activation at the level of spinal cord contributes to nociceptive 2 
processing 3 
VEGF-Axxxa and VEGF-Axxxb differ only in their terminal 6 amino acids. The C-terminal 4 
sequence determines the efficacy of VEGFR2 signaling of the isoforms and their 5 
functional properties [13]. On binding to VEGFR2, VEGF-Axxxa leads to full 6 
phosphorylation and activation of VEGFR2, whereas VEGF-Axxxb activates only partial 7 
VEGFR2 phosphorylation, leading to receptor degradation [4]. VEGF-A165b also 8 
antagonizes VEGF-Axxxa binding [88]. The different C-terminal sequences also 9 
determine the anti- or pro-nociceptive effects of the VEGF-A165b and VEGF-A165a 10 
isoforms respectively [35] but both isoforms promote neuroprotection [9,71]. Our 11 
findings above show that VEGF-A alternative splicing is altered in neuropathic states 12 
(Fig. 3-5), and this is associated with pain behaviors. These results suggest that spinal 13 
cord VEGFR2 activation by different VEGF isoforms could contribute to nociceptive 14 
processing. Despite evidence from clinical studies that demonstrate an involvement of 15 
VEGF receptors in pain [43,52], and experimental evidence showing that spinal VEGF 16 
levels are associated with pain [57], there are few published findings on the effects of 17 
VEGF-A in spinal nociceptive processing. As spinal VEGF-A splicing and isoform 18 
expression, and therefore by inference VEGFR2 activation, were altered in PSNI we 19 
determined the effect of VEGFR antagonism on central nociceptive processing. 20 
PTK787 (or vatalanib) is a tyrosine kinase inhibitor that has non-selective inhibitory 21 
actions on VEGFR1 and 2. It is 18-fold more selective for VEGFR1 and 2 over 22 
VEGFR3, and has slight selectivity for VEGFR2 (IC50 <50nM) over VEGFR1 (IC50 23 
~100nM) [86]. In naïve rats, systemic VEGFR antagonism with PTK787 (30mg/kg, i.p.) 24 
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increased thermal withdrawal latencies to heat (Fig. 8A n=5/group) indicating an 1 
analgesic effect. To determine the effect of PTK787 on one aspect of central 2 
nociceptive processing, we used the formalin test. Injection of formalin into the hind 3 
paw allows for the investigation of two distinct phases of acute nociceptive behavior. 4 
The initial phase (0-15min) is largely mediated by peripheral nerve activation, whereas 5 
the second has both a peripheral and central component. One hour prior to formalin 6 
injection, rats were treated with either (i.p.) vehicle or PTK787. The acute phase was 7 
unaffected (0-15min) by PTK787 treatment (Fig. 8B-E; n=7/group). In contrast the 8 
second phase (20-60 min) was significantly reduced by systemic PTK787 treatment 9 
for both the time of flinching (Fig. 8B& D) and the number of flinches (Fig. 8C & E). 10 
These results suggest a central component of VEGFR inhibition. To determine the 11 
targets of VEGF-A/VEGFR signaling in naïve rats, given the effects of the VEGFR 12 
antagonist on the second phase of the formalin test, we recorded electromyographic 13 
nociceptive withdrawals to selective nociceptor activation. Fast heating (fast heating 14 
rates ~7.5oC/s) preferentially activates myelinated A-nociceptors and slow heating 15 
activates unmyelinated C-nociceptors, both inducing a withdrawal from the stimulus. 16 
To determine VEGFR2 specific actions, ZM323881 (5-[[7-(benzyloxy) quinazolin-4-17 
yl]amino]-4-fluoro-2-methylphenol) was used locally. ZM323881 which has sub-18 
nanomolar potency and specificity for VEGFR2 (IC50<2nM) [85], with an IC50 greater 19 
than 50μM for VEGFR1 and PDGFR [85]. I.t. ZM323881 (100nM, specific VEGFR2 20 
inhibitor, [85]) led to a prolonged (up to 60 min) increase in the temperature at which 21 
the rats withdrew during A-nociceptor stimulation (Fig. 8F, n=3-5 per group). 22 
ZM323881 did not have a significant effect on C-nociceptor withdrawals (Fig. 8F). 23 
These results show that VEGFR2 signaling is mediated, at last in part, by A-nociceptor 24 
activation in the spinal cord. 25 
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Taken together, these results are consistent with the hypothesis that the VEGF-A 1 
isoforms may have different functions in the spinal cord, as in the periphery [35]. We 2 
tested this by giving VEGF agonists and antagonists intrathecally (i.t.), and measuring 3 
pain behaviors in mice and rats. PTK787 increased both mechanical withdrawal 4 
thresholds (Fig. 9A; n=3 mice/group, 6 hind-paws treated as replicates) and heat 5 
nociceptive withdrawal time (Fig. 9B) compared with vehicle treated mice. In contrast 6 
injection of 2.5nM VEGF-A165a reduced mechanical withdrawal thresholds (Fig. 9C; 7 
n=4 mice/group, 8 hind-paws treated as replicates) and heat withdrawal latencies (Fig. 8 
9D), indicating a central pro-nociceptive action of VEGF-A165a in naïve mice. 9 
Conversely, 2.5nM VEGF-A165b increased mechanical thresholds (Fig. 9E n=4 mice 10 
group, 8 hind-paws treated as replicates) and heat withdrawal latencies (Fig. 9F) 11 
indicating a central anti-nociceptive effect. In rats, administration of a neutralizing 12 
antibody against VEGF-Axxxb had a similar effect to that of VEGF-A165a, decreasing 13 
withdrawal thresholds to mechanical stimulation (Fig. 9G; n=3 rats group, 6 hind-paws 14 
treated as replicates) and the time taken for withdrawal from heat (Fig. 9H), indicating 15 
that loss of endogenous VEGF-Axxxb from the spinal cord is painful in naïve animals.  16 
 17 
Attenuation of central VEGFR2 signaling leads to alleviation of neuropathic pain  18 
We mimicked the effect of spinal SRPK1 inhibition by increasing the proportion of 19 
spinal VEGF-A165b with exogenous protein, 2 days after the onset of neuropathic pain 20 
behavior in rats. Intrathecal VEGF-A165b reversed both mechanical (Fig. 10A) and cold 21 
allodynia (Fig. 10B) and increased thermal withdrawal latencies both ipsilaterally (Fig. 22 
10C) and contralaterally (Fig. 10D). IP (30mg/kg) PTK787 led to the increase in 23 
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withdrawal latencies to heat both ipsilateral (Fig. 10E) and contralateral (Fig. 10F) in 1 
PSNI injured rats.  2 
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Discussion 1 
We show that the splicing factor kinase SRPK1 is a key regulator of spinal nociceptive 2 
processing in naïve and nerve injured animals. We present evidence for a novel 3 
mechanism in which altered SRSF1 localization/function in neuropathic pain results in 4 
sensitization of spinal cord neurons. Inhibiting the splicing factor kinase SRPK1 can 5 
control alternative splicing of VEGF-A isoforms in spinal cord, and can prevent the 6 
development of neuropathic pain. 7 
Alternative splicing and pain 8 
The development of neuropathic pain and associated neuronal excitation, results from 9 
alterations in neuromodulatory protein function, leading to sensitization of peripheral 10 
and central nociceptive systems. Both short and long term changes occur in the 11 
expression and function of ion channels, receptors, excitatory and inhibitory 12 
neurotransmitters/modulators and second/third messenger systems [15,78,79] 13 
leading to the regulation of neuronal excitability through modulation of excitatory 14 
and/or inhibitory networks. Many of these alterations can be attributable to altered 15 
protein expression (e.g. [61,66]). Alternative pre-mRNA splicing is a rapid, dynamic 16 
process, recognised to be important in many physiological processes, including in 17 
nociception [37]. Such splicing of many channels and receptors particularly calcium 18 
channels, is altered in pain states [3,56], but prior to our studies the control of 19 
mechanisms of alternative pre-mRNA splicing had not been considered as a 20 
contributory factor in nociceptive processing [35].  21 
Inhibition of SRPK1 alleviates neuropathic pain and reduces SRSF1 activation. 22 
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The splicing kinase SRPK1, a member of the serine-arginine-rich kinases, controls 1 
alternative pre-mRNA splicing of a relatively small number of identified RNAs [35]. To 2 
date, there is strong evidence for the involvement of only one of these, VEGF-A, in 3 
nociception [35,49,50,65,83]. SRPK1 controls the activity of splice factor SRSF1 that 4 
is fundamental to the processing of pre-mRNA transcripts [28], their cellular 5 
localization/transport [10], and it may also be involved in translational repression [19]. 6 
Phosphorylation and activation of SRSF1 results in nuclear translocation in a number 7 
of cell types [2,59]. After nerve injury activated SRSF1 was only found in the nuclei of 8 
injured (ATF-3 positive) large excitatory (vGLUT1 positive) neurofilament-rich DRG 9 
neurons whereas it was found in the cytoplasm of uninjured DRG neurons. 10 
Interestingly, SRSF1 was also seen in the central terminals of myelinated neurons 11 
after injury, but was not in central terminals in naïve animals. The nuclear localization 12 
suggests that neuronal SRSF1 is activated in mRNA processing in injured myelinated 13 
neurons [2]. The redistribution of cytoplasmic SRSF1 to central terminals may reflect 14 
a change in neuronal function or mRNA transport [77]. Little is understood of this 15 
function of SRSF1 in sensory neurons, although mRNA transport is closely linked to 16 
splicing, and specific mRNA splice variants can be targeted to axons [54].  17 
After traumatic nerve injury, injured DRG neurons (e.g. ATF3 positive) demonstrate 18 
ectopic and/or increased evoked activity. These neuronal phenomena arise due to 19 
expression changes in key mediators of sensory neuronal excitability, ultimately 20 
underlying chronic pain phenotypes [20,79]. Local neuro-immune interactions 21 
resulting from damage to neurons alter the properties of adjacent ‘uninjured’ afferents 22 
[20,79], including sensitization of A-fiber afferents [96], and together these drive 23 
excitability changes in the spinal cord [18]. Mechanisms such as SRPK1/SRSF1-24 
mediated alternative pre-mRNA splicing could underpin this ‘phenotypic switch’ 25 
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change in properties, for example by controlling relative expression of ion channel 1 
splice variants in damaged neurons [3,79]. Increased release of neurotransmitters and 2 
modulators from primary afferent central terminals is seen in the spinal cord following 3 
nerve injury [26]. The cellular SRSF1 redistribution also suggests that phosphorylated 4 
SRSF1 could act to transport RNAs to the central terminals in nerve injury, and hence 5 
enable translation of specific isoforms (e.g. VEGF-A165a) in the nerve terminals [26]. 6 
This reduction in the amount of SRSF1 present in afferent central terminals following 7 
intrathecal SRPK1 inhibition could be due to increased degradation of the SRPK1-8 
SRSF1 complex and/or reductions in transport of mRNA to the central terminals of 9 
primary afferents.  10 
In addition to peripheral sensitization, PSNI results in mechanical and cold 11 
hypersensitivity [34] and central sensitization [84]. Intrathecal administration of the 12 
SRPK1 inhibitor SRPIN340 abolished pain behaviors including mechanical allodynia 13 
and hyperalgesia, and cold allodynia, and the central sensitization indicated by spinal 14 
c-fos expression. Central hyperalgesic priming of primary afferent nociceptors is 15 
dependent on local protein translation in central terminals [23], so we speculate that 16 
SRPK1/SRSF1 actions on RNA localization or protein translation [10,19] may also 17 
contribute to this sensitization mechanism. As heat hyperalgesia was also reduced but 18 
PSNI animals did not display sensitization to radiant heat [33,84], this suggests that 19 
central SRPK1 inhibition not only prevents central sensitization, but also reduces 20 
activation of non-sensitized spinal nociceptive networks.  21 
VEGF splicing and VEGF-dependent nociceptive processing in spinal cord.  22 
SRPK1/SRSF1 controls the splice site choice in the alternative splicing of the vascular 23 
endothelial growth factor A (VEGF-A) family, leading to increased expression of 24 
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VEGF-Axxxa isoforms [2,25,59]. VEGF-Axxxa isoforms are widely known as pro-1 
angiogenic/cytoprotective factors and this splicing pathway is strongly associated with 2 
solid tumor development [2]. Peripheral administration of VEGF-A165a resulted in pain, 3 
as did, somewhat surprisingly, VEGFR2 blockade [35]. These findings are supported 4 
by observations that systemic VEGF-A receptor blockers result in pain in clinical 5 
studies [12,43] and painful experimental neuropathy [83]. In contrast, given 6 
intrathecally, the VEGF-R2 antagonist, PTK787 decreased hypersensitivity in naïve 7 
and neuropathic rodents (Fig. 8, and [50]), but VEGF-A165a again increased 8 
hypersensitivity in naïve (Fig. 8) and spinal cord injury rats [57]. This latter increase in 9 
pain was associated with aberrant myelinated fiber sprouting in dorsal horn and dorsal 10 
columns that may be VEGF-A dependent [57]. In contrast, van Neervan and 11 
colleagues [82] found only very small anti-nociceptive effects of intrathecal VEGF-12 
A165a on pain, and no effect on neuronal function. Observed differences in VEGF-A 13 
effects could be attributable to different concentrations used, the source of VEGF-14 
A165a, the degree of injury, or different endogenous isoform complement [6]. Clinically, 15 
elevated levels of VEGF-A in the spinal cord of neuropathic pain patients correlate 16 
with reported pain [52]. VEGF-A and VEGF-A receptor 2 are present in both peripheral 17 
and central nervous systems including spinal cord [7,9,72]. rhVEGF-A165a has 18 
consistent pro-nociceptive actions peripherally [35] and centrally, and our findings 19 
demonstrate that the different VEGF-A isoform subtypes have opposing actions on 20 
nociception in the spinal cord, as they do in the periphery [35]. We are the first to show 21 
that the alternatively spliced isoform, VEGF-A165b has anti-nociceptive actions in the 22 
spinal cord.  23 
Taken together our observations of: increased spinal splicing factor expression, 24 
increased spinal pro-nociceptive VEGF-A165a but unchanged VEGF-A165b expression, 25 
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and blockade of pain behavior and VEGF-A expression changes by SPRK1 inhibition, 1 
suggest that exogenous and endogenous VEGF-A isoforms modulate spinal 2 
nociceptive processing in naïve animals and after peripheral nerve injury. The sites of 3 
ligand/receptor expression, the differences in peripheral and central administration, 4 
and the current clinical use of many anti-VEGF treatments to treat varied diseases 5 
highlight the importance of recognizing the different functions and sites of action of the 6 
alternative VEGF-A isoforms.  7 
Myelinated afferents and neuropathic pain.  8 
We found that VEGFR2 blockade resulted in inhibition of A fiber nociceptor-mediated 9 
nociception, suggesting that endogenous VEGF is involved in spinal processing of A 10 
fiber nociceptor inputs. Irrespective of the animal model or human condition of 11 
neuropathic pain, the prevailing evidence is that afferents are sensitized [20,34] both 12 
C-fiber [1,14,20,38,40,68-70,96] and A-fiber nociceptors [81,96], increasing the 13 
afferent barrage to the spinal cord through enhanced stimulus-evoked responses 14 
and/or increases in spontaneous/ongoing firing. Other mechanisms, such as neuro-15 
immune interactions, can also contribute to changes in spinal excitability [80]. The 16 
result of increased input to and excitability of spinal neurons is central sensitization 17 
[46] leading to hyperalgesia and allodynia. It has been hypothesized that central 18 
sensitization allows low threshold A-fiber afferents to “access” pain pathways [48,79] 19 
although precise mechanisms are unknown. Early reports of low threshold A fiber 20 
mechanoreceptors (LTMs) sprouting into superficial laminae [91] are still debated 21 
[32,87]. A-fiber nociceptive afferents, as opposed to LTMs, have similar central 22 
terminals in superficial dorsal horn laminae (I and IIo) in both naïve and nerve injured 23 
animals [87] and may represent the afferents expressing SRSF1. What is clear is that 24 
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altered central processing of myelinated nociceptor information contributes to 1 
neuropathic pain [55,75,98], such as secondary dynamic allodynia [41]. Both C-fiber 2 
(unmyelinated) and A-fiber (myelinated) pathways can contribute to chronic pain 3 
[48,98], but this is the first time that VEGFR2 has been implicated in the processing of 4 
information in these pathways. If VEGFR2 is involved in A-fiber nociceptive pathways, 5 
then this provides a potential new mechanism for the modulation of nociception. 6 
Conclusion 7 
Here we identify a novel pathway of nociceptive processing through a SRPK1-SRSF1-8 
VEGF-Axxxa axis in myelinated nociceptors that is involved in nociception at the level 9 
of the spinal cord. During neuropathic pain development SRPK1 drives expression of 10 
pro-nociceptive VEGF-Axxxa at the level of the spinal cord. Therefore the development 11 
of SRPK1 targeted therapy, or other controls for alternative splicing, would be 12 
interesting targets for novel analgesic agent development [21]. These findings 13 
highlight the importance of understanding control of RNA function, including alternative 14 
splicing in relation to pain, and considering specific interactions of splice factors in 15 
excitatory networks following peripheral nerve trauma.  16 
 17 
 18 
  19 
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Figures and Legends 1 
Figure 1. SRSF1 expression and activation in DRG sensory neurons following PSNI 2 
injury 3 
[A-C] SRSF1 (Red) was expressed in the cytoplasm (not co-localized with DAPI) of 4 
the DRG sensory neurons in naïve animals. [D] Replacement of the primary antibody 5 
with a species matched IgG control DRG image resulted in no staining. [E-G] SRSF1 6 
was co-localized with nuclear stain DAPI in DRG sensory neurons following PSNI 7 
injury (arrows). In some neurons cytoplasmic SRSF1 is still evident (arrowheads). [H] 8 
Omission of the primary antibody resulted in no staining. [I & J] Representative 9 
examples of ATF3 expression in NeuN-co-labeled DRG sensory neurons in [I] naïve 10 
and [J] PSNI animals. [K] The number of ATF3 positive DRG neurons was significantly 11 
increased in the L4 from PSNI animals (unpaired t test, n=5/group). [L-O] High 12 
magnification representative images of SRSF1/ATF3/NeuN co-labeled DRG neurons. 13 
(white arrows).  ** p<0.001. Scale bars = 50µm low magnification and 20µm high 14 
magnification. 15 
 16 
Figure 2. SRSF1 expression in NF200 sensory neurons 17 
[A-C] SRSF1 expression in the cytoplasm of NF-200-positive L4 dorsal root ganglia 18 
neurons in the naïve animal. [C] Note the clear cytoplasmic localization of the 19 
SRSF1 (arrows).  [D-F] Following PSNI, clear SRSF1 nuclear translocation was 20 
evident in the NF200 positive neurons (arrows in F). [G] SRSF1 was not expressed 21 
in IB4 positive dorsal root ganglia neurons, [H] though SRSF1 is co-localized with 22 
nuclear marker DAPI.  [I-K] SRSF1 was also localized to NF200-rich sensory nerve 23 
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fibers of the PSNI saphenous nerve. [L] Quantification of the SRSF1 positive and 1 
total number of sensory neurons in the dorsal root ganglia by cell cross-sectional 2 
area (µm2) in naïve and PSNI injured rats. Scale bars = 50µm. N=5 per group. 3 
 4 
Figure 3. SRSF1 is expressed in myelinated central terminals in the dorsal horn of 5 
the spinal cord and increased after PSNI 6 
[A] SRSF1 was expressed at low levels in the dorsal horn of the spinal cord in naïve 7 
animals. [B] vGLUT1 was used as a marker of myelinated sensory fiber central 8 
terminals. [C] Merged image of SRSF1 and vGLUT1. [D-F] Two days after PSNI 9 
nerve injury there was an increase of SRSF1 expression in the spinal cord, still co-10 
localized with vGLUT1. [F] Inset images of no primary SRSF1 (i) and vGlut1 (ii) 11 
antibodies. [G-I] High power views of boxes marked in D-F. [J] Increased SRSF1 12 
expression/localization within the lumbar spinal cord following PSNI was 13 
demonstrated by western blot with two different primary antibodies (Santa Cruz 14 
mouse monoclonal and Abcam rabbit polyclonal antibodies). [K] Quantification of 15 
increased expression post-PSNI in spinal cord vs. naïve rats (Abcam antibody, Mann 16 
Whitney U test, p=0.055, n=3) [L] Using coloc2 analysis through determination of 17 
Pearson correlation coefficient, there was an increase in the degree of co-18 
localization between vGLUT1 and SRSF1 immunoreactivity in the spinal cord 19 
following PSNI, compared to naïve (**p<0.01 Mann Whitney test, n=4 per group). [M] 20 
SRSF1 was expressed in DRG neurons that were [N] positive for vGLUT1, a marker 21 
of excitatory large diameter DRG neurons. [O] Overlay of vGLUT1 and SRSF1 22 
images. [P & Q] Representative images of SRSF1 stained spinal cord sections used 23 
for analysis, showing the contralateral dorsal horn from [P] a naïve and [Q] PSNI 24 
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animal. [R & S] The same images of contralateral dorsal horns showing VGLUT1 1 
staining in [R] naïve and [S] PSNI animals (Scale bars = 50µm). 2 
 3 
Figure 4. VEGFxxxa isoform expression increases in the spinal cord following PSNI.  4 
[A-F] Immunofluorescence of VEGF in the naïve ([A] ipsilateral [B] contralateral), 5 
PSNI ([C] ipsilateral [D] contralateral) and PSNI+SRPIN ([E] ipsilateral [F] 6 
contralateral) spinal cord (superficial dorsal horn located in top right of images) using 7 
the pan-VEGF-A antibody A20. [G-I] Co-localization of pan-VEGF-A with SRSF1 in 8 
the dorsal horn of the lumbar spinal cord (high magnification images). [J] Western 9 
blot of protein extracted from spinal cords of 6 animals, three naïve and three after 10 
PSNI. Pan-VEGF-A but not VEGF-A165b increased after PSNI. [K]. Densitometric 11 
analysis of the Western blot showed a large increase in pan-VEGF-A expression, no 12 
increase in VEGF-Axxxb expression and [L] a reduction in the proportion of VEGF-13 
Axxxb after PSNI versus naïve animals (one way ANOVA, Sidak post hoc test, 14 
*p<0.05, (F(3,6)=1.347), n=3 per group). Scale bars = 50µm. 15 
 16 
Figure 5. Inhibition of SRPK1 activity in the spinal cord prevents neuropathic pain 17 
Intrathecal (i.t.) SRPIN340 treatment in rats completely prevented [A] mechanical (F 18 
test (2,20) = 3.539), [B] dynamic brush allodynia (F (2,20) = 5.526) and [C] cooling 19 
allodynia (F (2, 20) = 7.8) after PSNI (n=9, PSNI + vehicle, n=6, PSNI + SRPIN340) 20 
in the ipsilateral hindpaw. Contralateral hind-paws were not different between groups 21 
following mechanical, brush and cooling nociceptive testing. Withdrawal latencies 22 
were increased both [D] ipsilaterally (F(2,20) = 25.86) and [E] contralaterally (F(2, 23 
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20) = 12.72) following i.t. SRPIN340 treatment. (*p<0.05, **p<0.01, ***p<0.001 two 1 
way ANOVA with post-hoc Bonferroni tests). 2 
 3 
Figure 6. PSNI increases and intrathecal SRPIN340 reduces SRSF1 expression in 4 
the spinal dorsal horn.  5 
[A-C] SRSF1 immunoreactivity in vGLUT1-positive terminals in the spinal cord after 6 
PSNI. (C shows the co-localization of SRSF1 and vGLUT1). [D-F] Intrathecal 10µM 7 
SRPIN340 reduced SRSF1 immunoreactivity in vGLUT1-positive terminals. [F] 8 
indicates that there is a loss of expression of SRSF1 but not vGLUT-1. [G] 9 
Quantification of SRSF1/vGLUT1 fluorescence intensity by area. PSNI increased 10 
SRSF1 staining and SRPIN340 treatment led to a reduction in SRSF1 11 
immunostaining within the dorsal horn 2 days after PSNI (F (2,9) =11.16, *p<0.05, 12 
**p<0.01 one way ANOVA with post-hoc Bonferroni test; n=4 per group). [H] 13 
Intrathecal SRPIN 340 treatment in PSNI injured animals demonstrate a reduction in 14 
colocalisation between vGLUT1 and SRSF1 compared to PSNI+vehicle group 15 
(**p<0.01, Mann Whitney test, n=4 per group). 16 
 17 
Figure 7. Inhibition of SRPK1 in the spinal cord following PSNI leads to reduction in 18 
VEGF-Axxxa expression. 19 
[A] Immunoblotting for pan-VEGF-A, VEGF-Axxxb and tubulin expression in spinal 20 
cord from 4 PSNI animals treated with vehicle or SRPIN340. [B] Quantification of 21 
intensity showed that the amount of VEGF-Axxxb increased slightly, and pan-VEGF-A 22 
reduced resulting in [C] a restoration of the VEGF-A165b ratio in PSNI towards that in 23 
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naïve control animals (compare with Fig. 3H, one way ANOVA, *p<0.05 Sidak test 1 
(F(3,6)=3.529) n=3 per group). [D-E] C-fos immunostaining in spinal cord dorsal horn 2 
in PSNI animals treated with either i.t. vehicle or SRPIN340. [F]. Increased spinal 3 
neuronal activation, indicated by increased numbers of c-fos expressing dorsal horn 4 
neurons after PSNI, was blocked by PSNI+SRPIN340 treatment (one way ANOVA 5 
with post Bonferroni test, *** p<0.001, (F(2, 9) = 36.50), n=4 per group for c-fos 6 
expression). [G] SRPK1 was expressed in the lumbar spinal cord in the naïve 7 
animal, and was unchanged post-PSNI (n=3 per group, NS) Scale bar=40μm. 8 
 9 
Figure 8. VEGF receptor 2 blockade leads to attenuation of nociceptive pain 10 
behavior in rats. 11 
[A] Intraperitoneal injection of 30mg/kg PTK787 led to an increased withdrawal 12 
latency to heat (two way ANOVA with post-hoc Bonferroni test n=5/group, **p<0.01, 13 
(F(1,20) = 5.388). Intraperitoneal 30mg/kg PTK787 attenuated both [B] time (F (11, 14 
132) = 13.39) and [C] number (F)11, 132) = 4.015) of formalin-induced pain 15 
behaviors within the second phase (two way ANOVA with post-hoc Bonferroni test, 16 
*p<0.05, **p<0.01, n=7/group). Area under the curve analysis of [D] duration (F(1,12) 17 
= 5.874) and [E] number (F (1,12) = 8.739) for the two phases of nociceptive 18 
behaviors shown in B & C (**p<0.01, ***p<0.001 two way ANOVA with post-hoc 19 
Bonferroni test). [F] Intrathecal injection of 200nM of VEGFR2 antagonist ZM323881 20 
led to an increase in EMG response threshold only to A-nociceptor stimulation 21 
versus baseline and vehicle groups (**p<0.01; two way ANOVA with post Bonferroni) 22 
(n=3-5/group). 23 
 24 
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Figure 9. Alteration of spinal VEGFR activation attenuates nociceptive behavior in 1 
naïve mice and rats 2 
[A] Intrathecal administration of 200nM PTK787 increased mechanical withdrawal 3 
thresholds (F(1,10) = 12.47) and [B] increased withdrawal latency to heat in mice 4 
(F(1, 12) = 8.165, n=4/group vehicle, (8 hind paws used as replicates), n=3/group  5 
PTK787, (6 hind paws used as replicates), **p<0.01 two-way ANOVA with post-hoc 6 
Bonferroni test). [C] Intrathecal VEGF-A165a reduced mechanical thresholds (F(1,12) 7 
= 17.18) and [D] heat (F(1,12) = 18.61) withdrawal latencies in mice (n=4/group (8 8 
hind paws used as replicates). [E] Intrathecal VEGF-A165b increased mechanical 9 
thresholds (F(1,12) = 25.26) and [F] thermal (F(1,16) = 5.631) response latencies in 10 
mice (n=4 vehicle group (8 hind paws used as replicates), n=5 VEGF group, (10 hind 11 
paws used as replicates)). [G] Treatment of rats with a VEGF-A165b neutralizing 12 
antibody decreased both mechanical thresholds (F(1, 15) = 18.66) and [H] thermal 13 
latencies ((F(1,15) = 1.400,  n=3 group (6 hind paws used as replicates), two way 14 
ANOVA with post-hoc Bonferroni test, ***p<0.001). 15 
 16 
Figure 10. Attenuation of VEGFR2 signaling leads to alleviation of neuropathic pain 17 
in rats 18 
Intrathecal application of VEGF-A165b two days after PSNI surgery abolished [A] 19 
mechanical (F(2, 10) = 32.39) and [B] cooling (F(2, 20) = 14.03) allodynia (n=6 per 20 
group), and increased withdrawal latencies to heat in both [C] ipsilateral (F (2,20) = 21 
4.201) and [D] contralateral hind paws (F (2,10) = 3.476, two way ANOVA with post-22 
hoc Bonferroni test, *p<0.05, **p<0.01, ***p<0.001, n=6 per group). Contralateral 23 
hind-paws from both groups did not differ in nociceptive behavioral response to [A] 24 
Hulse et al. 2016 
 
 51 
mechanical and [B] cooling stimulation. IP 30mg/kg PTK787 led to increased 1 
withdrawal latencies to heat in the [E] ipsilateral (F(2,12)=2.45) and [F] contralateral 2 
limb (F(2,12)=1.38)) (two way ANOVA with post-hoc Bonferroni test, **p<0.01, n=4 3 
per group). 4 
  5 
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